Oxalic Acid

Oxalic Acid

SCHEMBL5780417

COc1ncccc1CN1CCC(C=Cc2cc(C)cc(C)c2)CC1.O=C(O)C(=O)O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
POLB P06746 1/20 0.39
NPY2R P49146 1/20 0.39
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
ACHE P22303 2/20 0.37
ACKR3 P25106 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
BCHE P06276 1/20 0.37
CHRM4 P08173 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL5816767 0.86 MEN1 (0.40) MEN1KMT2APOLBKDM4EALDH1A1
Oxalic Acid SCHEMBL5781446 0.86 MEN1 (0.46) MEN1KMT2APOLBNPY2RKDM4E
Oxalic Acid SCHEMBL5782417 0.85 TSHR (0.43) MEN1KMT2APOLBKDM4EALDH1A1
Oxalic Acid SCHEMBL5779745 0.82 MEN1 (0.48) MEN1KMT2APOLBKDM4EACHE
SCHEMBL5783876 0.80 MAOB (0.39) MEN1KMT2ANPY2RACKR3MAPT
SCHEMBL5782945 0.79 PDCD1LG2 (0.41) NPY2RACHEMAPTBCHECHRM4
SCHEMBL5781196 0.78 ACHE (0.44) ALDH1A1ACHEBCHE
SCHEMBL5783845 0.78 KDM4E (0.43) MEN1KMT2AKDM4EALDH1A1ACHE
SCHEMBL5780164 0.77 CHRNB4 (0.43) KMT2AKDM4EALDH1A1ACHEACKR3
SCHEMBL5780436 0.76 ALDH1A1 (0.39) MEN1KMT2APOLBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1254904-B1 NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME EISAI CO LTD (JP) 2006-05-24 EP disclosed
US-6784192-B2 NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC EISAI CO., LTD. (JP) 2004-08-31 US disclosed
US-20030220368-A1 Novel piperidine compouds and drugs containing the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2003-11-27 US disclosed
EP-1254904-A1 NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME Eisai Co., Ltd. (JP) 2002-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220368-A1 Novel piperidine compouds and drugs containing the same TRPV1, CACNA1D, KCND2 MEN1 3216/4885KMT2A 1308/4885POLB 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.